相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ETS-1 Oncogenic Activity Mediated by Transforming Growth Factor α
Chet E. Holterman et al.
CANCER RESEARCH (2010)
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Gong-Hong Wei et al.
EMBO JOURNAL (2010)
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Bas J. Wouters et al.
BLOOD (2009)
Targeting the RAF-MEK-ERK pathway in cancer therapy
Clara Montagut et al.
CANCER LETTERS (2009)
CIP2A Is Associated with Human Breast Cancer Aggressivity
Christophe Come et al.
CLINICAL CANCER RESEARCH (2009)
Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy
Paul Dent et al.
DRUG RESISTANCE UPDATES (2009)
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Anchit Khanna et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Young-Kwang Yoon et al.
MOLECULAR CANCER THERAPEUTICS (2009)
DNA Specificity Determinants Associate with Distinct Transcription Factor Functions
Peter C. Hollenhorst et al.
PLOS GENETICS (2009)
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2008)
Mechanisms of MYC stabilization in human malignancies
Melissa R. Junttila et al.
CELL CYCLE (2008)
CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells
Wenjuan Li et al.
CLINICAL CANCER RESEARCH (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Charles E. Massie et al.
EMBO REPORTS (2007)
CIP2A inhibits PP2A in human malignancies
Melissa R. Junttila et al.
CELL (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
N Normanno et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
ETS transcription factors and their emerging roles in human cancer
A Seth et al.
EUROPEAN JOURNAL OF CANCER (2005)
Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth
JC Hahne et al.
ONCOGENE (2005)
Functional genetics and experimental models of human cancer
JJ Zhao et al.
TRENDS IN MOLECULAR MEDICINE (2004)
Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors
PC Hollenhorst et al.
NUCLEIC ACIDS RESEARCH (2004)
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer
LS Hoo et al.
ONCOGENE (2002)
The ETS-domain transcription factor family
AD Sharrocks
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
